01—Abstract
Summary
Summary of the 10-Q filed October 29, 2024. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation's Form 10-Q for the quarter ended September 30, 2024 shows a sharp swing to a nine-month net loss of $168.6 milliona, versus net income of $396.5 million in the prior-year period, driven mainly by a $679.4 million in-process R&D charge tied to the May 30, 2024 acquisition of Escient Pharmaceuticals for $782.5 million in cash.
Third-quarter results were profitable: total revenues were $1.14 billionb, up from $919.0 million, and net income was $106.5 million ($0.54 diluted EPS), compared with $171.3 million a year earlier. Product revenues rose to $963.0 million, led by JAKAFI at $741.2 million and OPZELURA at $139.3 million, and the MINJUVI/MONJUVI revenue increase reflected the February 2024 acquisition of global tafasitamab rights. Cash and capital position declined materially during the period.
Cash and cash equivalents fell to $1.30 billionc from $3.21 billion at year-end 2023, largely because of the roughly $2.0 billion share repurchase completed in June 2024 through a modified Dutch auction tender offer at $60.00 per share and a related purchase from the Baker Entities. Net cash used in operating activities was $45.9 million for the nine months, compared with $348.8 million provided a year earlier. Total stockholders' equity decreased to $3.17 billion from $5.19 billion, and the company had no borrowings under its $500.0 million revolving credit facility.
The filing also highlights several contingent items. Accrued royalties of $469.5 milliond owed to Novartis are tied to the outcome of a contract dispute over U.S. JAKAFI royalties, and the company has accrued approximately $106.9 million relating to possible Medicaid rebates if OPZELURA were treated as a line extension of JAKAFI, a matter it is contesting in litigation against CMS. Research and development expense for the nine months rose to $2.14 billion, including the Escient charge and a $100.0 million MacroGenics milestone payment.
02—Key points
Key Highlights
- Nine-month net loss of $168.6 million versus net income of $396.5 million a year earlier, primarily due to the $679.4 million Escient acquired in-process R&D expense recognized in Q2 2024.
- Third-quarter total revenues of $1.14 billion, up from $919.0 million; net income of $106.5 million, or $0.54 diluted EPS, versus $171.3 million and $0.76 a year earlier.
- JAKAFI net revenues were $741.2 million in Q3 2024 versus $636.3 million in Q3 2023, and OPZELURA net revenues were $139.3 million versus $91.8 million.
- Cash and cash equivalents declined to $1.30 billion from $3.21 billion at December 31, 2023, reflecting the roughly $2.0 billion share repurchase completed in June 2024.
- Net cash used in operating activities was $45.9 million for the nine months, compared with $348.8 million provided in the prior-year period, attributed to the Escient acquisition and working capital changes.
- Accrued royalties of $469.5 million payable to Novartis depend on the outcome of a contract dispute regarding JAKAFI U.S. royalties, and $106.9 million has been accrued for possible OPZELURA-related Medicaid rebates pending the CMS line-extension litigation.
- Pipeline milestones cited include NIKTIMVO (axatilimab-csfr) FDA approval in August 2024, positive Phase 3 inMIND topline results for tafasitamab in follicular lymphoma, and the planned sBLA filing for retifanlimab in squamous cell anal cancer by year-end 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Incyte kept $0.09.
- Revenue$1.14B100.0%
- Cost of revenue−$86.0M7.6%
- Gross profit$1.05B92.4%
- Operating costs−$905.8M79.6%
- Operating income$146.1M12.8%
- Interest, other & tax−$39.6M3.5%
- Net income$106.5M9.4%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 29, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $1.14B$919.02M | +23.8% |
| Cost of Revenue | $85.99M$60.09M | +43.1% |
| Gross Profit | $1.05B$858.93M | +22.5% |
| R&D Expenses | $573.17M$375.71M | +52.6% |
| SG&A Expenses | $309.21M$267.89M | +15.4% |
| Operating Expenses | $991.79M$704.32M | +40.8% |
| Operating Income | $146.09M$214.71M | −32.0% |
| Net Income | $106.46M$171.27M | −37.8% |
| EPS (Basic) | $0.55$0.76 | −27.6% |
| EPS (Diluted) | $0.54$0.76 | −28.9% |
| Shares Outstanding (Basic) | 192.63M224.08M | −14.0% |
| Shares Outstanding (Diluted) | 195.84M226.17M | −13.4% |
05—Questions
Frequently Asked Questions
Why did Incyte report a net loss for the first nine months of 2024?
The nine-month net loss of $168.6 million was driven mainly by $679.4 million of in-process R&D expense recognized in the second quarter from the Escient Pharmaceuticals acquisition, which was accounted for as an asset acquisition. The company also recorded $100.0 million in MacroGenics milestone expense in R&D during the period, partially offset by $126.2 million of realized and unrealized gains on equity investments, mainly from Merus shares.
How much did Incyte spend on share repurchases, and how did it affect the balance sheet?
The company repurchased a total of 33,325,849 shares at $60.00 per share in June 2024 for an aggregate purchase price of approximately $2.0 billion, including 27,866,666 shares through the tender offer and 5,459,183 shares from the Baker Entities. Cash used in financing activities was $2.04 billion for the nine months, and total stockholders' equity fell to $3.17 billion from $5.19 billion at year-end 2023.
What drove revenue growth in the third quarter of 2024?
Total revenues rose to $1.14 billion from $919.0 million, with product revenues, net of $963.0 million, led by JAKAFI ($741.2 million) and OPZELURA ($139.3 million). MINJUVI/MONJUVI revenue increased to $31.4 million from $8.3 million, reflecting the February 2024 acquisition of global rights to tafasitamab. Milestone and contract revenues were $18.0 million, and product royalty revenues were $156.9 million.
What are the main contingent liabilities or disputes disclosed in the filing?
The filing discloses accrued royalties of $469.5 million to Novartis, payment of which depends on the outcome of a contract dispute over JAKAFI U.S. royalties. Incyte has also accrued approximately $106.9 million for incremental Medicaid rebates that would be owed if OPZELURA were considered a line extension of JAKAFI, and it has filed a lawsuit against CMS over this issue. The impact on OPZELURA gross-to-net deductions for the quarter is approximately 6.7%.
How much liquidity does Incyte have, and does it have debt?
At September 30, 2024, the company held $1.30 billion in cash and cash equivalents and $467.2 million in marketable securities, plus $3.3 million in short-term equity investments. It had no outstanding borrowings under its $500.0 million unsecured revolving credit facility, which was extended to June 2027, and it stated that its cash flow, existing cash and facility funds should be adequate for its capital needs for the foreseeable future.
06—Continue